Literature DB >> 22328325

Sample size re-estimation for survival data in clinical trials with an adaptive design.

Kanae Togo1, Manabu Iwasaki.   

Abstract

In clinical trials with survival data, investigators may wish to re-estimate the sample size based on the observed effect size while the trial is ongoing. Besides the inflation of the type-I error rate due to sample size re-estimation, the method for calculating the sample size in an interim analysis should be carefully considered because the data in each stage are mutually dependent in trials with survival data. Although the interim hazard estimate is commonly used to re-estimate the sample size, the estimate can sometimes be considerably higher or lower than the hypothesized hazard by chance. We propose an interim hazard ratio estimate that can be used to re-estimate the sample size under those circumstances. The proposed method was demonstrated through a simulation study and an actual clinical trial as an example. The effect of the shape parameter for the Weibull survival distribution on the sample size re-estimation is presented.
Copyright © 2010 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 22328325     DOI: 10.1002/pst.469

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.

Authors:  Zhiwei Jiang; Ling Wang; Chanjuan Li; Jielai Xia; Hongxia Jia
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

2.  Blinded and unblinded sample size reestimation in crossover trials balanced for period.

Authors:  Michael J Grayling; Adrian P Mander; James M S Wason
Journal:  Biom J       Date:  2018-08-03       Impact factor: 2.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.